Amgen's immunology drug results —The Novo Nordisk Senate hearing —Sanofi's soul-searching Read on to learn more.

After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, taking up the top science spot at Sanofi.

Sanofi named a new chief scientific officer this week, part of a series of moves aimed at redefining the company.

Sanofi has appointed Mike Quigley, a former executive at Gilead and Bristol Myers Squibb, as the French pharma's next chief ...

Mike Tyson and Jake Paul's upcoming fight has been dismissed as "not real" by iconic boxing commentator Jim Lampley, who joins many critics in questioning the legitimacy of the bout. Originally ...

Sanofi Consumer Healthcare India Limited has been listed on the BSE and National Stock Exchange (NSE). SCHIL’s demerger from Sanofi India Limited, executed under the Scheme of Arrangement, was ...

Miami Dolphins head coach Mike McDaniel has announced who will assume the team's QB1 role while Tua Tagovailoa is in concussion protocol. McDaniel said that the Dolphins will proceed with Tua's ...

10, and founding member Mike Shinoda spoke about the rockers' "new chapter" with lead singer Emily Armstrong of Dead Sara seven years after Chester Bennington died by suicide in 2017. Shinoda ...

Joe Rogan has urged Mike Tyson to provide more substantial evidence of his fitness ahead of his highly anticipated bout with Jake Paul on November 15. At 58, Tyson's return to professional boxing ...

In 2020, Sanofi invested nearly 500 million euros ($554 million) to build what it then called its Evolutive Vaccine Facility (EVF). The idea later evolved into including the manufacture of biologics.

Sanofi has made a late entry to the radioligand party, paying 100 million euros ($110 million) upfront for global rights to a neuroendocrine tumor treatment that is nearing a filing for approval.

As part of its effort to develop innovative treatments for people living with rare cancers, Sanofi has entered into an exclusive licensing agreement with RadioMedix, Inc., a US clinical-stage ...